Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER.
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER vs CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, leading to cell lysis and death. It has activity against both gram-positive and gram-negative bacteria.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g intravenously every 8-12 hours; typical dose 1 g IV q12h for most infections, 2 g IV q8h for severe infections.
1-2 g IV every 8-12 hours; maximum 12 g/day
None Documented
None Documented
Approximately 2 hours in adults with normal renal function; prolonged to 4–8 hours in mild-to-moderate renal impairment and up to 13–30 hours in severe impairment (CrCl <30 mL/min).
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (≥85% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal excretion minimal (<1%).
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic